Hidden by HIPAA: The Costs of Cure
- 1 June 2005
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 3663-3665
- https://doi.org/10.1200/jco.2005.11.951
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- The Metabolic Syndrome and Disturbances in Hormone Levels in Long-Term Survivors of Disseminated Testicular CancerJournal of Clinical Oncology, 2005
- Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular CancerJournal of Clinical Oncology, 2003
- Excessive annual BMI increase after chemotherapy among young survivors of testicular cancerBritish Journal of Cancer, 2003
- Syndrome X in testicularcancer survivorsThe Lancet, 2001
- Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular CancerJNCI Journal of the National Cancer Institute, 1997
- Evaluation of long-term toxicity after chemotherapy for testicular cancer.Journal of Clinical Oncology, 1996
- Acute leukaemia following chemotherapy including etoposide for testicular carcinomaAustralian and New Zealand Journal of Medicine, 1993
- Hypercholesterolemia after chemotherapy for testis cancer.Journal of Clinical Oncology, 1992
- Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumoursThe Lancet, 1991
- Second malignancies following testicular cancer, ovarian cancer and hodgkin's disease: An international collaborative study among cancer registriesInternational Journal of Cancer, 1987